Page 1

Иvalneva VALNEVA SE Campus Bio - Ouest | 6 , Rue Alain Bombard 44800 Saint - Herblain , France Valneva Reports Nine - Month 2021 Revenue and Cash Strong financial position • Cash and cash equivalents of € 247.9 million at the end of September 2021 ○ Reflects $ 107.6 million of gross proceeds raised in a US IPO and placement in Europe in the second quarter of 2021 Does not include $ 102.0 million of gross proceeds raised in a follow - on offering in the US and Europe in the fourth quarter of 2021 Total revenue ( excluding COVID ) of € 69.8 million in the first nine months of 2021 compared to € 58.8 million in the first nine months of 2020 . • Product sales of € 45.5 million in the first nine months of 2021 ( € 45.9 million in the first nine months of 2020 ) € 24.3 million of Other Revenues ( revenues from collaborations , licensing and services ) in the first nine months of 2021 ( € 12.9 million in the first nine months of 2020 ) Updated 2021 financial guidance ( excluding COVID ) • Total revenues , excluding VLA2001 , now expected between € 85 million and € 100 million ( compared to € 80 million to € 105 million previously ) R & D expenses , excluding VLA2001 , now expected between € 60 million to € 70 million ( compared to € 65 million to € 75 million previously ) Valneva confirms that Peter Bühler will join the Company as Chief Financial Officer on January 1 , 2022 and has appointed Vincent Dequenne , formerly Senior Vice President Operations , as Chief Operating Officer . Key Milestones Achieved in 2021 include : Lyme Disease Vaccine Candidate VLA15 • Further positive Phase 2 results reported , including booster response Inactivated COVID - 19 Vaccine Candidate VLA2001 • Positive pivotal Phase 3 Results reported 。 Superiority in terms of neutralizing antibody titer levels compared to comparator vaccine , AstraZeneca's AZD1222 00 ○ Non - inferiority in terms of seroconversion rates Significantly better tolerability profile than comparator Advance Purchase Agreement approved by European Commission ( EC ) for up to 60 million doses Single - Shot Chikungunya Vaccine Candidate VLA1553 • Positive pivotal Phase 3 results reported Raised approximately $ 210 million • Successful Nasdaq Initial Public Offering ( IPO ) and concurrent placement in Europe Successful follow - on offering in the US and Europe November 18 , 2021 VALNEVA SE